Aura Biosciences (AURA) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Aura Biosciences is the larger company by market cap ($669.9 million vs $626.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | AURA | PROK |
|---|---|---|
| Share price | $6.46 | $1.57 |
| Market cap | $669.93M | $626.72M |
| 1-day change | +4.70% | -1.87% |
| YTD return | +18.53% | — |
| 1-year return | +12.15% | — |
| EPS (TTM) | $-1.75 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $3.48 |
| 52-week low | $4.73 | $1.30 |
| Distance from 52-week high | -32.25% | -54.89% |
| Average volume | 748.04K | 1.31M |
| Shares outstanding | 103.70M | 208.93M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
AURA vs PROK FAQ
Which is bigger, Aura Biosciences or ProKidney?
Aura Biosciences (AURA) is larger, with a market capitalization of $669.93M compared with $626.72M for ProKidney (PROK).
Are Aura Biosciences and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.